Evidence-based Approach for the Management of Post-myocardial Infarction with or without Left Ventricular Dysfunction

Please Note: This CME activity has expired. You may continue to view the material for educational purposes, but this activity is no longer eligible for CME credit.

Course Objectives:
This educational monograph is directed towards US-based cardiologists, interventional cardiologists, and electrophysiologists.

Upon the completion of this activity, you should be able to:

1. Identify and discuss the management of cardiovascular risk factors as advocated in treatment guidelines for ST-elevation myocardial infarction patients.
2. Discuss the role of implantable cardioverter-defibrillator device therapy in the post-myocardial infarction patient.
3. Identify and contrast the available pharmacologic treatment options for the management of cardiovascular risk factors in the post-myocardial infarction patient.
4. Identify possible reasons for the underutilization of β-blockers in secondary prevention regimens in the post-myocardial infarction patient.

Accreditation:
Millennium CME Institute, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Millennium CME Institute, Inc. designates this educational activity for a maximum of 2.0 Category 1 Credits toward the AMA Physician’s Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.

This activity was prepared in accordance with the ACCME Essentials.

This activity was reviewed for relevance, accuracy of content, balance of presentation, and time required for participation by Ronald S. Freudenberger, MD; Issac Tawfik, MD.

Release Date: December 2004

Expiration Date: December 31, 2005

© 2004 Millennium CME Institute, Inc. and UMDNJ—Center for Continuing and Outreach Education

Faculty Disclosure:
Millennium CME Institute, Inc. endorses the Accreditation Council for Continuing Medical Education Standards for Commercial Support. Every effort has been made to encourage faculty to disclose any commercial relationships or personal benefit with companies whose products are discussed in educational presentations. Disclosure of a relationship is not intended to suggest or condone bias in any presentation, but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

The faculty listed below have declared that they have no financial arrangements or affiliations with any corporate organization offering financial support or grant monies for this CME program or with any corporate organization whose product(s) will be discussed in their presentation(s):

• Michaeline Daboul
• Karen Doherty, PharmD
• David C. Howard
• Steven N. Singh, MD
• Issac Tawfik, MD

The faculty listed below have declared the following arrangements and/or affiliations:

• Barry H. Greenberg, MD: Grant/Research Support—Aventis; Consultant—GlaxoSmithKline, Pfizer; Speakers Bureau—GlaxoSmithKline, Merck, Pfizer
• Stephen L. Kopecky, MD: Grant/Research Support—Bristol-Myers Squibb; Consultant—GlaxoSmithKline
• Gerald V. Naccarelli, MD: Grant/Research Support—Guidant, Medtronic; Consultant—AstraZeneca, Aventis, GlaxoSmithKline, Guidant, Medtronic, Pfizer, Reliant, Wyeth-Ayers
• Bramah N. Singh, MD, DPhil, FRCP: Consultant—CV Therapeutics, Sanofi-Aventis; Speakers Bureau—AstraZeneca, CV Therapeutics
• Clyde W. Yancy, MD, FACC, FAHA: Grant/Research Support—GlaxoSmithKline; Consultant—GlaxoSmithKline; Speakers Bureau—GlaxoSmithKline; Other Affiliation—Medtronic, Novartis, Scios
• Ronald S. Freudenberger, MD: Grant/Research Support—Cardiome Pharma, GlaxoSmithKline, Medtronic; Consultant—Medtronic; Speakers Bureau—GlaxoSmithKline, Medtronic, Pfizer; Stock Shareholder—GlaxoSmithKline

Signed Disclosure forms are on file at Millennium CME Institute, Inc.

This monograph is not intended as a sole source of guidance for the management of post-myocardial infarction with or without left ventricular dysfunction. It has been designed to assist the clinician in evaluating the latest evidence-based medicine and is not intended to replace clinical judgment or establish a protocol for all patients.

This CME-certified monograph does not contain information on commercial products that is outside of current approved labeling or information on the investigational use of products not yet approved by the United States Food and Drug Administration (FDA). Approved labeling should be consulted prior to treating patients with products discussed herein.

Directions:
The learner should read the learning objectives and study the publication. After analyzing the material, the learner should complete the self-assessment test consisting of a series of multiple-choice questions.

Upon completing this activity as designed, described above, participants will receive a letter of credit awarding AMA/PRA Category 1 Credits six (6) weeks after receipt of the test, registration, and evaluation materials.

Estimated time to complete this activity as designed is 2.0 hours.

CME Testing Options